{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:16:42Z","timestamp":1772000202375,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.nmd.2024.01.005","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T17:27:45Z","timestamp":1705685265000},"page":"28-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Effect of nusinersen treatment on quality of life and motor function in adult patients with spinal muscular atrophy"],"prefix":"10.1016","volume":"36","author":[{"given":"Nazan","family":"\u015eim\u015fek Erdem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-8318","authenticated-orcid":false,"given":"G\u00f6k\u00e7e Ya\u011fmur","family":"G\u00fcne\u015f Gencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abir","family":"Alaamel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilmi","family":"Uysal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.nmd.2024.01.005_bib0001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.nmd.2024.01.005_bib0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fmolb.2016.00007","article-title":"Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases","volume":"3","author":"Butchbach","year":"2016","journal-title":"Front Mol Biosci"},{"issue":"1","key":"10.1016\/j.nmd.2024.01.005_bib0003","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/71709","article-title":"A mouse model for spinal muscular atrophy","volume":"24","author":"Hsieh-Li","year":"2000","journal-title":"Nat Genet"},{"issue":"15","key":"10.1016\/j.nmd.2024.01.005_bib0004","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev"},{"issue":"11","key":"10.1016\/j.nmd.2024.01.005_bib0005","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","article-title":"Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3","volume":"91","author":"Maggi","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.nmd.2024.01.005_bib0006","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3 - a prospective observational study","volume":"6","author":"Walter","year":"2019","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"10.1016\/j.nmd.2024.01.005_bib0007","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/mus.26769","article-title":"Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience","volume":"61","author":"Veerapandiyan","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2024.01.005_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420907803","article-title":"Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen","volume":"13","author":"Jochmann","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.nmd.2024.01.005_bib0009","article-title":"Assessment of health-related quality of life in adult spinal muscular atrophy under nusinersen treatment-a pilot study","volume":"12","author":"Thimm","year":"2021","journal-title":"Front Neurol"},{"issue":"6","key":"10.1016\/j.nmd.2024.01.005_bib0010","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1007\/s00415-021-10954-3","article-title":"Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen","volume":"269","author":"Bonanno","year":"2022","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.nmd.2024.01.005_bib0011","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2024.01.005_bib0012","doi-asserted-by":"crossref","unstructured":"M.C. Pera, G. Coratti, N. Forcina, E.S. Mazzone, M. Scoto, J. Montes, A. Pasternak, A. Mayhew, S. Messina, M. Sframeli, M. Main, R.M. Lofra, T. Duong, D. Ramsey, S. Dunaway, R. Salazar, L. Fanelli, M. Civitello, R. de Sanctis, L. Antonaci, L. Lapenta, S. Lucibello, M. Pane, J. Day, B.T. Darras, D.C. De Vivo, F. Muntoni, R. Finkel, E. Mercuri, Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy, 17(1) (2017) 39.","DOI":"10.1186\/s12883-017-0790-9"},{"issue":"9\u201310","key":"10.1016\/j.nmd.2024.01.005_bib0013","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the hammersmith functional motor scale for SMA II and III patients","volume":"17","author":"O'Hagen","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10.1016\/j.nmd.2024.01.005_bib0014","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1093\/brain\/awq270","volume":"133","author":"Compston","year":"2010","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.nmd.2024.01.005_bib0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"18","key":"10.1016\/j.nmd.2024.01.005_bib0016","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.nmd.2024.01.005_bib0017","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.nmd.2024.01.005_bib0018","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3233\/JND-190453","article-title":"Prospective cohort study of nusinersen treatment in adults with spinal muscular atrophy","volume":"7","author":"Yeo","year":"2020","journal-title":"J Neuromuscul Dis"},{"issue":"7","key":"10.1016\/j.nmd.2024.01.005_bib0019","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s10072-023-06698-9","article-title":"Nusinersen for adults with spinal muscular atrophy","volume":"44","author":"Arslan","year":"2023","journal-title":"Neurol Sci"},{"issue":"11","key":"10.1016\/j.nmd.2024.01.005_bib0020","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/ene.15501","article-title":"Nusinersen in adult patients with 5q spinal muscular atrophy: a multicenter observational cohorts' study","volume":"29","author":"V\u00e1zquez-Costa","year":"2022","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.nmd.2024.01.005_bib0021","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00415-020-10223-9","article-title":"Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4","volume":"268","author":"De Wel","year":"2021","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.nmd.2024.01.005_bib0022","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1212\/WNL.0000000000009914","article-title":"Nusinersen in adult patients with spinal muscular atrophy: observations from a single center","volume":"95","author":"Moshe-Lilie","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.nmd.2024.01.005_bib0023","first-page":"76","article-title":"Muscle quantitative MRI in adult SMA patients on nusinersen treatment: a longitudinal study","volume":"41","author":"Gallone","year":"2022","journal-title":"Acta Myol."},{"issue":"5","key":"10.1016\/j.nmd.2024.01.005_bib0024","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/mus.25148","article-title":"Correlates of health related quality of life in adult patients with spinal muscular atrophy","volume":"54","author":"Kruitwagen-Van Reenen","year":"2016","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.nmd.2024.01.005_bib0025","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13023-020-1339-3","article-title":"Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review","volume":"15","author":"Wan","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.nmd.2024.01.005_bib0026","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/104990910201900109","article-title":"Assessment of pain and health-related quality of life in slowly progressive neuromuscular disease","volume":"19","author":"Abresch","year":"2002","journal-title":"Am J Hosp Palliat Care"},{"issue":"1","key":"10.1016\/j.nmd.2024.01.005_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13010110","article-title":"Health-related quality of life in spinal muscular atrophy patients and their caregivers-a prospective, cross-sectional, multi-center analysis","volume":"13","author":"Wohnrade","year":"2023","journal-title":"Brain Sci"},{"issue":"13","key":"10.1016\/j.nmd.2024.01.005_bib0028","doi-asserted-by":"crossref","first-page":"e1206","DOI":"10.1212\/WNL.0000000000006241","article-title":"Patient reported impact of symptoms in spinal muscular atrophy (PRISM-SMA)","volume":"91","author":"Mongiovi","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.nmd.2024.01.005_bib0029","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/mus.26201","article-title":"Social participation of adult patients with spinal muscular atrophy: frequency, restrictions, satisfaction, and correlates","volume":"58","author":"Kruitwagen-van Reenen","year":"2018","journal-title":"Muscle Nerve"},{"issue":"16","key":"10.1016\/j.nmd.2024.01.005_bib0030","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1080\/09638288.2018.1555864","article-title":"Psychological well-being in adults with spinal muscular atrophy: the contribution of participation and psychological needs","volume":"42","author":"Fischer","year":"2020","journal-title":"Disabil Rehabil"},{"key":"10.1016\/j.nmd.2024.01.005_bib0031","doi-asserted-by":"crossref","unstructured":"N.B. Johnson, A.D. Paradis, S. Naoshy, J. Wong, J. Montes, D.C. Krasinski, Evaluation of nusinersen on impact of caregiver experience and hrqol in later-onset spinal muscular atrophy (SMA): results from the phase 3 Cherish trial (1429), AAN Enterprises, 2020.","DOI":"10.1212\/WNL.94.15_supplement.1429"},{"key":"10.1016\/j.nmd.2024.01.005_bib0032","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/j.nmd.2020.08.268","article-title":"SMA\u2013THERAPY: P. 269 impact of continued nusinersin treatment on caregiver experience and health-related quality of life in later-onset SMA: results from the SHINE study","volume":"30","author":"Montes","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.01.005_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.626787","article-title":"Quality of life in SMA patients under treatment with nusinersen","volume":"12","author":"Mix","year":"2021","journal-title":"Front Neurol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624000245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624000245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T19:33:40Z","timestamp":1731785620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896624000245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":33,"alternative-id":["S0960896624000245"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2024.01.005","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of nusinersen treatment on quality of life and motor function in adult patients with spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2024.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}